Board of Directors

Geoffrey Pearce

Non-Executive Director, Chairman

Mr Pearce is a Melbourne-based entrepreneur with over three decades of business experience.

Mr Pearce esablished Pearce Pharmaceuticals, a trading company in raw materials for the drug and veterinarian industries as well as packaging for the cosmetics and beauty industry. Mr Pearce expanded this business to create and own Scental Pacific Pty Ltd, a full service contract manufacturer servicing the bath, body and beauty industry. He grew this business to a turnover of over $25 million and in excess of 150 staff. In 1996 Mr Pearce sold Scental Pacific Pty Ltd to the Smorgan family while retaining and expanding his Pearce Pharmaceuticals trading business into the Continental Group. In 2002, Mr Pearce re-established himself as a contract manufacturer in the bath and beauty industry with the acquisition of a small factory. In 2010, he renamed that business as Beautiworx. In 2014, Mr Pearce sold Beautiworx into a company where he was one of the two major shareholders, CEO of the manufacturing arm and a director on the Board. This company, BWX Limited, was successfully listed on the ASX in 2015 with a current market capitalisation of over $400 million being a Brand business vertically integrated with manufacturing and distribution.

Greg Lan

Non-Executive Director

Mr Lan joined the Probiotec board in February 2017. Mr Lan was the founding Managing Director of Sydney-based pharmaceutical company Aspen Pharmacare Australia, a subsidiary of South African listed Aspen Pharmacare Holdings. During Mr Lan’s tenure, Aspen Australia experienced exponential growth, particularly after the acquisition of Sigma’s branded and generics portfolio in 2011 (as well as its manufacturing facilities), and is today one of Australia’s largest pharmaceutical companies, with a diverse portfolio of over 260 products covering prescription and OTC. When Mr Lan retired after 15 years with the company, Aspen’s Asia Pacific operations (including Australia) had annualised sales in excess of $1 billion.

Prior to joining Aspen, Mr Lan has had extensive experience working in the pharmaceutical industry internationally, including senior roles with Ciba-Geigy (now Novartis) in Switzerland and Saudi Arabia, as well as with Sanofi-Aventis in Australia. Mr Lan holds an MBA from the University of Michigan.

Alexander Beard

Non-Executive Director

Mr Beard has extensive experience with investee businesses, both in providing advice and in direct management roles, especially bringing management expertise to early-stage businesses. He has implemented management information systems, financial reporting systems, and internal operating and control procedures. He has also assisted businesses in value engineering product ranges and introducing market-oriented product lines.

Mr Beard has implemented significant company restructuring and recruited new management teams for growth businesses. His negotiation experience includes successes in private placement and in contractual arrangements involving banking facilities, distribution arrangements and processing agreements.

Wesley Stringer

Executive Director, Chief Executive Officer

Prior to joining Probiotec, Mr Stringer was employed by KPMG in Taxation and Finance. He has also worked internationally for Deutsche Bank and BNP Paribas Investment Bank in London.

Qualifications: B.Comm (Accounting, Finance), LLB (hons), CPA.